Date: 2014-07-01
Type of information: Licensing agreement
Compound: Politrate®/Lutrate® (leuprolide acetate 3.75 mg)
Company: Zeltia (Spain) Pharma Mar (Spain) GP Pharm (Spain)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: Lutrate® (leuprolide acetate 3.75 mg) is an agonist of luteinizing-hormone-releasing hormone (LHRH), a class of drugs that reduce the secretion of testosterone (a sex hormone).
Disease: prostate cancer
Details: * On July 1, 2014, Grupo Zeltia announced that Pharma Mar, S.R.L., an Italian subsidiary of Pharma Mar, S.A., has signed a licence agreement with GP Pharm under which Pharma Mar S.R.L. will distribute GP Pharm\'s drug Politrate® (Leuprorelin) in Italy. Politrate®—marketed in other countries under the Lutrate® brand—has been approved by 23 countries of the European Union for the treatment of prostate cancer, and a reimbursement price has also been approved.
The agreement designates Pharma Mar S.R.L. as the sole distributor of Politrate® in Italy; the product will be supplied to Pharma Mar S.R.L. by GP Pharm. PharmaMar plans to begin distributing Politrate® in Italy in October. Initially the one-month dosage will be distributed, with plans to subsequently add the three month dose.
The agreement covers distribution of Politrate® but not manufacture, which will be entrusted to GP Pharm. Accordingly, the agreement does not entail additional investment by PharmaMar and it will use its existing infrastructure in Italy to distribute the drug.
Financial terms:
Latest news:
